SLC5A2 and endothelial dysfunction: Major advances in the management of DM and its cardiovascular complications have been discovered recently, including pharmacological innovations such as sodium glucose cotransporter 2-inhibitors, glucagon-like peptide 1 receptor agonists, and risk factor amelioration including home blood pressure monitoring and endothelial dysfunction reduction [45–49].